BRCA1 and prostate cancer: Specifically, AR antagonists demonstrate contextual synthetic lethality with PARPi by modulating the expression of key HR proteins such as BRCA1/2 and RAD51, and potentially enhance the vulnerability of prostate cancer cells on alternative DNA repair mechanisms, such as PARP-mediated repair (71).